On February 19, 2020 NeuroVive Pharmaceutical AB reported that Year End Report January – December 2019 (Press release, NeuroVive Pharmaceutical, FEB 19, 2020, View Source;december-2019-301007315.html [SID1234554533])
Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:
Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing
Schedule Your 30 min Free Demo!
Important events in 2019
KL1333
NeuroVive enrolls first subject in its European KL1333 phase Ia/b clinical study
NeuroVive initiates second part of its ongoing KL1333 Phase Ia/b clinical study
NeuroVive completes recruitment of healthy volunteers in the second part of its ongoing KL1333 clinical Phase Ia/b study
NV354
NeuroVive initiates NV354 preclinical safety studies and scales up compound production
NeuroSTAT
NeuroVive’s IND for clinical development of NeuroSTAT approved by FDA
NeuroSTAT receives Fast Track designation from the US Food and Drug Administration
Financials
NeuroVive is supplied with approximately MSEK 99.0 in share issue proceeds
NeuroVive receives SEK 28.2 Million in a directed new share issue
Strategy and communications
NeuroVive updates its strategy and sharpens its focus on primary mitochondrial diseases
NeuroVive hosts the company’s first Capital Markets Day
NeuroVive hosts the Mitochondria Day for the second time
Other
NeuroVive announces settlement in dispute with CicloMulsion AG
Important events after the reporting period
NeuroVive proposes a rights issue of approximately MSEK 74 before issue costs. The rights issue is guaranteed to 90%.
Financial information fourth quarter (Oct-Dec 2019)*
Net revenues: KSEK 49 (5)
Other operating income: KSEK 1,000 (1,009)
Loss before tax: KSEK 27,112 (19,978)
Loss per share: SEK -0.15 (-0.25)
Diluted loss per share: SEK -0.15 (-0.25)
Financial information full year 2019 (Jan-Dec 2019)*
Net revenues: KSEK 34 (5)
Other operating income: KSEK 3,500 (2,461)
Loss before tax: KSEK 77,000 (73,494)
Loss per share: SEK 0.45 (0.94)
Diluted loss per share: SEK 0.45 (0.94)
* APM Alternative perfomance measures, see definition on page 17 in the Report.
The complete Year End report is available for download below and through NeuroVive’s web site www.neurovive.com.
The information was submitted for publication, through the agency of the contact person set out below at 08:40 a.m. CET on 19 February 2020.